SCHEMBL4625947

SCHEMBL4625947

Cc1cc(SSc2cc(C)c3ncc(C(N)=O)c(Cl)c3c2)cc2c(Cl)c(C(N)=O)cnc12

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.77
NNMT P40261 5/20 0.39
PDE4B Q07343 6/20 0.37
PARP1 P09874 2/20 0.37
PIM1 P11309 1/20 0.36
TTK P33981 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
BTK Q06187 1/20 0.36
KCNH2 Q12809 1/20 0.35
ATM Q13315 1/20 0.35
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
PDE4A P27815 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SIRT3 Q9NTG7 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5321604 0.82 SLC2A1 (0.63) SLC2A1NNMTPDE4BPARP1PIM1
SCHEMBL5464747 0.76 SLC2A1 (0.56) SLC2A1NNMTMEN1KMT2A
SCHEMBL4627675 0.74 SLC2A1 (0.48) SLC2A1NNMTPDE4BKCNH2ATM
SCHEMBL4300282 0.74 SLC2A1 (0.54) SLC2A1NNMTPDE4BPARP1PIM1
SCHEMBL7622343 0.72 SLC2A1 (0.50) SLC2A1NNMTPARP1PIM1TTK
SCHEMBL7494095 0.71 SLC2A1 (0.50) SLC2A1PARP1MEN1KMT2ATDP1
SCHEMBL17646064 0.70 SLC2A1 (0.50) SLC2A1NNMTPARP1PIM1TTK
SCHEMBL4656774 0.70 SLC2A1 (0.49) SLC2A1PDE4BMEN1KMT2A
SCHEMBL2483995 0.70 NPSR1 (0.50) SLC2A1NNMTPARP1PIM1TTK
SCHEMBL4607457 0.69 SLC2A1 (0.49) SLC2A1BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096884-A1 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors GLAXO GROUP LIMITED (GB) 2008-04-24 US disclosed
US-20080096884-A1 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors GLAXO GROUP LIMITED (GB) 2008-04-24 US disclosed
US-20080096884-A1 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors GLAXO GROUP LIMITED (GB) 2008-04-24 US disclosed
EP-1673086-B1 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS GLAXO GROUP LTD (GB) 2008-01-23 EP disclosed
EP-1673086-B1 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS GLAXO GROUP LTD (GB) 2008-01-23 EP disclosed
EP-1673086-A1 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-28 EP disclosed
WO-2005030212-A1 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2005-04-07 WO disclosed
WO-2005030212-A1 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096884-A1 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors PDE4A, PDE4B, PDE3B SLC2A1 4263/4885NNMT 811/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.